- NEWS FEATURE
- Clarification 07 April 2022
The quest to prevent MS — and understand other post-viral diseases
A small number of people infected with Epstein-Barr virus (pictured) go on to develop multiple sclerosis years later. Credit: Dr Gopal Murti/SPL
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
204,58 € per year
only 4,01 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 603, 784-786 (2022)
doi: https://doi.org/10.1038/d41586-022-00808-x
Updates & Corrections
-
Clarification 07 April 2022: An earlier version of this story stated that Katherine Luzuriaga is the lead investigator on the mRNA-1189 trial. She is, in fact, the lead investigator only for the UMass Chan part of the trial.
References
Bjornevik, K. et al. Science 375, 296–301 (2022).
Lanz, T. V. et al. Nature 603, 321–327 (2022).
Cohen, J. I. Clin. Transl. Immunol. 4, e32 (2015).
Luzuriaga, K. & Sullivan, J. L. N. Engl. J. Med. 362, 1993–2000 (2010).
Messick, T. E. et al. Sci. Transl. Med. 11, eaau5612 (2019).
Lebrun-Frenay, C. et al. Ann. Neurol. 88, 407–417 (2020).
Douaud, G. et al. Nature https://doi.org/10.1038/s41586-022-04569-5 (2022).
Long COVID’s long R&D agenda
The four most urgent questions about long COVID
Pandemics disable people — the history lesson that policymakers ignore